POINT Biopharma Global Inc. [NASDAQ: PNT] disclosed that it has partnered with Convergent Therapeutics Inc to assess CONV 01-α (Rosopatamab-225Ac) in combination with PNT2002 for progressive metastatic castration-resistant Prostate Cancer. The study has started patient addition. The trial was carried out at Weill Cornell Medicine with Dr. Scott T. Tagawa.
The Phase I/II trial is registering more than 33 sufferers with progressive mCRPC who have got a prior androgen receptor signaling inhibitor (ARSI) and taxane chemotherapy and are PSMA PET-positive. The open-label Phase I dose-escalation portion of the study is intended to check the maximum tolerated dose (MTD) for the combination of CONV 01-α and PNT2002.
PNT2002 will be injected at the dose utilized in POINT Biopharma’s Phase III SPLASH trial. Furthermore, the increasing doses of CONV 01-α will be injected simultaneously. It was commenced with doses earlier shown to be well-tolerated. After the Phase I study has begun the MTD of the CONV 01-α and PNT2002 combination, investigators will commence the Phase II expansion study at MTD.
Furthermore, POINT Biopharma disclosed that the combination therapies are a very thrilling opportunity in the radiopharmaceutical space, as shown by Dr. Bander’s research into combining different radioligand therapies to enhance outcomes. Presently, PNT2002 has demonstrated potential as a monotherapy and the firm believes that this partnership has the potential to not only enhance patient outcomes but also offer sufferers and physicians new therapeutic options for advanced prostate cancers.